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A systematic method was developed to assemble functional full-length genomes of large RNA and DNA
viruses. Coronaviruses contain the largest single-stranded positive-polarity RNA genome in nature. The ;30-
kb genome, coupled with regions of genomic instability, has hindered the development of a full-length infec-
tious cDNA construct. We have assembled a full-length infectious construct of transmissible gastroenteritis
virus (TGEV), an important pathogen in swine. Using a novel approach, six adjoining cDNA subclones that
span the entire TGEV genome were isolated. Each clone was engineered with unique flanking interconnecting
junctions which determine a precise systematic assembly with only the adjacent cDNA subclones, resulting in
an intact TGEV cDNA construct of ;28.5 kb in length. Transcripts derived from the full-length TGEV con-
struct were infectious, and progeny virions were serially passaged in permissive host cells. Viral antigen pro-
duction and subgenomic mRNA synthesis were evident during infection and throughout passage. Plaque-pur-
ified virus derived from the infectious construct replicated efficiently and displayed similar plaque morphology
in permissive host cells. Host range phenotypes of the molecularly cloned and wild-type viruses were similar
in cells of swine and feline origin. The recombinant viruses were sequenced across the unique interconnecting
junctions, conclusively demonstrating the marker mutations and restriction sites that were engineered into the
component clones. Full-length infectious constructs of TGEV will permit the precise genetic modification of the
coronavirus genome. The method that we have designed to generate an infectious cDNA construct of TGEV
could theoretically be used to precisely reconstruct microbial or eukaryotic genomes approaching several
million base pairs in length.
Molecular genetic analysis of the structure and function of
RNA virus genomes has been profoundly advanced by the
availability of full-length cDNA clones, the source of infectious
RNA transcripts that replicate efficiently when introduced into
permissive cell lines (2, 9). Recombinant DNA technology has
allowed the isolation of infectious cDNA clones from a num-
ber of positive-stranded RNA viruses, including picornavi-
ruses, caliciviruses, alphaviruses, flaviviruses, and arteriviruses,
whose RNA genomes range in size from ;7 to 15 kb in length
(1, 13, 32, 34, 35, 47, 48, 54). The availability of these clones has
enhanced our understanding of the molecular mechanisms of
viral replication and pathogenesis and resulted in new ap-
proaches for heterologous gene expression and vaccine devel-
opment.
The order Nidovirales includes mammalian positive-polarity
single-stranded RNA viruses in the arterivirus and coronavirus
families (10, 16). The Coronaviridae family includes the Coro-
navirus and Torovirus genera (10, 46). Despite significant size
differences (;13 to 32 kb), the polycistronic genome organi-
zation and regulation of gene expression from a nested set of
subgenomic mRNAs are similar for all members of the order
(16, 46). The family Coronaviridae contains the largest RNA
viral genomes in nature (26, 44). Transmissible gastroenteritis
virus (TGEV), a group I coronavirus, contains a ;28.5-kb
genomic RNA that is packaged into a helical nucleocapsid
structure and surrounded by an envelope that contains three
virus-specific glycoprotein spikes, including the S glycoprotein,
membrane glycoprotein (M), and a small envelope glycopro-
tein (E) (17, 18, 33, 36). The TGEV genome is polycistronic
and encodes eight large open reading frames (ORFs), which
are expressed from full-length or subgenome-length mRNAs
during infection (17, 42, 43). The 59-most ;20 kb encode the
RNA replicase genes, which are encoded in two large ORFs,
designated 1a and 1b, the latter of which is expressed by ribo-
somal frameshifting (3, 17). ORF1a encodes at least two viral
proteases and several other nonstructural proteins, while ORF1b
contains polymerase, helicase, and metal-binding motifs typical
of an RNA polymerase (3, 17, 19). In the 39-most ;9 kb of the
TGEV genome, each of the downstream ORFs is preceded by
a highly conserved intergenic sequence element, which directs
the synthesis of each of the six or seven subgenomic RNAs
(11, 17, 18, 52). These subgenomic mRNAs are arranged in a
nested set structure from the 39 end of the genome, and each
contains a leader RNA sequence derived from the 59 end of
the genome (26, 29, 42, 43). Subgenomic mRNAs are gener-
ated by a discontinuous transcription mechanism, the details of
which are somewhat controversial (4, 40, 42, 43). In addition to
the viral mRNAs, full-length and subgenome-length negative-
strand RNAs are implicated in mRNA synthesis (4, 26, 40, 42,
43). Another unique feature of coronavirus replication is the
high RNA recombination frequencies associated with infection
(6, 25, 26).
The large size of the coronavirus genome, coupled with the
inability to clone portions of the polymerase gene in microbial
vectors, has hampered the ability to perform precise manipu-
lations and reverse genetics in members of the Coronaviridae
(17, 18, 26, 44). Recently these problems were overcome when
a full-length cDNA of TGEV was stably cloned in bacterial
artificial chromosome (BAC) vectors (3). In this report, we
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describe a simple and rapid approach for systematically assem-
bling a full-length, infectious cDNA construct of TGEV using
a series of smaller subclones and a novel strategy which theo-
retically may allow the assembly of large microbial or eukary-
otic chromosomes approaching several million base pairs in
length.
MATERIALS AND METHODS
Virus and cells. The Purdue strain (ATCC VR-763) of TGEV was obtained
from the American Type Culture Collection (ATCC) and passaged once in the
swine testicular (ST) cell line. ST cells were obtained from the ATCC (ATCC
1746-CRL) and maintained in minimal essential medium (MEM) containing
10% fetal clone II (HyClone) and supplemented with 0.5% lactalbumin hydro-
lysate, 13 nonessential amino acids, 1 mM sodium pyruvate, kanamycin (0.25
mg/ml), and gentamicin (0.05 mg/ml). Baby hamster kidney cells (BHK) were
maintained in alpha-MEM containing 10% fetal calf serum supplemented with
10% tryptose phosphate broth, kanamycin (0.25 mg/ml), and gentamicin (0.05
mg/ml). Feline kidney cells (CRFK) were maintained in Eagle’s MEM with
nonessential amino acids, Earle’s balanced salt solution, and 10% fetal bovine
serum at 37°C. Wild-type TGEV or viruses (icTGEV) derived from the full-
length construct were plaque purified twice, and stocks were grown in ST cells as
described (42, 43). To measure the growth rate of different viruses, cultures of ST
cells (5 3 105) were infected with wild-type TGEV or various molecularly cloned
isolates at a multiplicity of infection (MOI) of 5 for 1 h. The cells were washed
twice with phosphate-buffered saline (PBS) to remove residual virus and incu-
bated at 37°C in complete medium. At different times postinfection, progeny
virions were harvested and assayed by plaque assay in ST cells. To study the host
range phenotype, cultures of ST or CRFK cells (105) were infected with wild-type
or molecularly cloned icTGEV at an MOI of 5 for 1 h and fixed at 12 h
postinfection for fluorescent analysis (FA).
Mutagenesis, cloning, and sequencing of the TGEV genome. The cloning
strategy for a full-length TGEV construct is illustrated in Fig. 1 and is based on
the observation that the BglI restriction endonuclease cleaves at a specific se-
quence palindrome (GCCNNNN2NGGC) but leaves highly variable 3-nucleo-
tide ends that do not randomly self-assemble. Rather, these DNAs will only
anneal with fragments containing the complementary 3-nucleotide overhang
generated at identical BglI sites. The TGEV genome was cloned from infected
ST cell intracellular RNA by reverse transcription-PCR (RT-PCR) using primer
pairs directed against the Purdue strain of TGEV or a Taiwanese isolate (11, 17,
33) (Table 1). To create unique junction sites for assembly of a full-length TGEV
cDNA construct, primer-mediated PCR mutagenesis was used to insert unique
BglI restriction sites at the 59 and 39 ends of each subclone (Table 1, Fig. 1).
These primer pairs do not alter the coding sequence and result in RT-PCR
amplicons ranging in size from ;5.0 to 6.9 kb in length. Total intracellular RNA
was isolated from TGEV-infected cells using RNA STAT-60 reagents according
to the manufacturer’s directions (Tel-TEST B, Inc.). To isolate the TGEV
subclones, reverse transcription was performed using Superscript II and oligo-
deoxynucleotide primers according to the manufacturer’s recommendations
(Gibco-BRL). Following cDNA synthesis at 50°C for 1 h, the cDNA was dena-
tured for 2 min at 94°C and amplified by PCR with Expand Long Taq polymerase
(Boehringer Mannheim Biochemicals) for 25 cycles at 94°C for 30 s, 58°C for 25
to 30 s, and 68°C for 1 to 7 min depending on the size of the amplicon. The PCR
amplicons were isolated from agarose gels and cloned into Topo II TA (Invitro-
gen) or pGem-TA cloning vectors (Promega) according to the manufacturer’s
directions.
Three to seven independent clones of each TGEV amplicon were isolated and
sequenced using a panel of primers located about 0.5 kb from each other on the
TGEV insert and an ABI model automated sequencer. A consensus sequence for
each of the cloned fragments was determined, and when necessary (i.e., pTGEV
A, pTGEV B1, pTGEV C, and pTGEV F), a consensus clone was assembled
using restriction enzymes and standard recombinant DNA techniques to remove
unwanted amino acid changes associated with reverse transcription or naturally
occurring quasispecies variation.
Assembly of a full-length TGEV infectious construct. Each of the plasmids was
grown to high concentration, isolated, and digested or double-digested with BglI,
BstXI, or NotI according to the manufacturer’s direction (NEB) (Fig. 1A). The
TGEV A clone was digested with ApaI, treated with calf intestine alkaline
phosphatase, and subsequently digested with BglI, resulting in a ;6.3-kb frag-
ment. The TGEV F clone was NotI digested, treated with calf alkaline phospha-
tase, and then BglI digested. All other vectors were digested with BglI or BstXI.
The appropriately sized cDNA inserts were isolated from 0.8 to 1.2% agarose
gels in TAE buffer (Tris, acetate EDTA) containing 5 mM cytidine (Fluka) and
extracted using Qiaex II gel extraction kits according to the manufacturer’s
directions (Qiagen Inc., Valencia, Calif.). Cytidine was incorporated to reduce
DNA damage associated with cumulative UV exposure during visualization in
agarose gels (21). Appropriate cDNA subsets (A1B1, B21C, and DE-11F)
were pooled into 100- to 300-ml aliquots, and equivalent amounts of each DNA
were ligated with T4 DNA ligase (15 U/100 ml) at 16°C overnight in 30 mM
Tris-HCl (pH 7.8)–10 mM MgCl2–10 mM dithiothreitol–1 mM ATP. Appropri-
ately sized products (A/B1, B2/C, and DE-1/F) were separated in 0.7% agarose
gels containing 5 mM cytidine as described, isolated, and religated as described
above. The final products were purified by phenol-chloroform-isoamyl alcohol
(1:1:24) and chloroform extraction and precipitated under ethanol prior to in
vitro transcription reactions. The full-length TGEV construct is designated
TGEV 1000.
The nucleocapsid protein may function as part of the transcriptional complex
(7, 15, 26). To provide N protein in trans, the TGEV N gene was amplified from
the TGEV F clone using primer pairs flanking the N gene ORF. The upstream
primer contained an SP6 site (59-TCGGCCTCGATTTAGGTGACACTATA
GATGGCCAACCAGGGACAACG-39), while the downstream primer intro-
duced a 14-nucleotide oligo(T) stretch, providing a poly(A) tail following in
vitro transcription (59-TTTTTTTTTTTTTTAGTTCGTTACCTCGTCAATC-
39). The TGEV leader RNA sequence, 39-most ORF, and noncoding sequences
were not present in this construct. The PCR product was purified from gels and
used directly for in vitro transcription.
RNA transfection. Full-length transcripts of the TGEV cDNA, TGEV 1000,
were generated in vitro as described by the manufacturer (mMessage mMachine;
Ambion, Austin, Tex.) with certain modifications. For 2 h at 37°C, several 30-ml
reactions were performed that were supplemented with 4.5 ml of a 30 mM GTP
stock, resulting in a 1:1 ratio of GTP to cap analog. Similar reactions were
performed using 1 mg of PCR amplicons encoding the TGEV N gene sequence
or Sindbis virus noncytopathic replicons encoding green fluorescent protein
(pSin-GFP; kindly provided by Charlie Rice, Washington University) and a 2:1
ratio of cap analog to GTP (1). The transcripts were treated with DNase I,
denatured, and separated in 0.5% agarose gels in TAE buffer containing 0.1%
sodium dodecyl sulfate. Alternatively, the transcripts were either treated with 50
ng of RNase A for 15 min at room temperature, DNase I treated, or directly
electroporated into BHK cells.
BHK or ST cells were grown to subconfluence, trypsinized, washed twice with
PBS, and resuspended in PBS at a concentration of 107 cells/ml. RNA transcripts
were added to 800 ml of the cell suspension in an electroporation cuvette, and
three electrical pulses of 850 V at 25 mF were given with a Bio-Rad Gene Pulser
II electroporator. The BHK cells were seeded with 106 uninfected ST cells in a
75-cm2 flask and incubated at 37°C for 3 to 4 days. Virus progeny were then
passaged in ST cells in 75-cm2 flasks at 2-day intervals and purified twice by
plaque assay.
Immunofluorescence assays. Cells were grown on LabTek chamber slides
(four or eight wells) and infected with wild-type TGEV or molecularly cloned
viruses (icTGEV-1, icTGEV-2, and icTGEV-3) generated from the infectious
construct. At 12 h postinfection, cells were fixed in acetone-methanol (1:1) and
stored at 4°C. Fixed cells were rehydrated in PBS (pH 7.2) and incubated with a
1:100 dilution of mouse anti-TGEV polyclonal antiserum for 30 min at room
temperature. After three washes in PBS, the cells were incubated with a 1:100
dilution of goat anti-mouse immunoglobulin G-fluorescein isothiocyanate con-
jugate (Sigma) for 30 min at room temperature. After three additional washes
with PBS, the cells were visualized and photographed under a Zeiss LSM110
confocal fluorescence microscope. Images were digitized and assembled in Pho-
toshop 5.5 (Adobe Systems Inc.).
RT-PCR to detect marker mutations and sequence analysis. Cultures of ST
cells were infected for 1 h at room temperature with wild-type TGEV or plaque-
purified icTGEV-1 and icTGEV-3 viruses that were derived from the infectious
construct. Intracellular RNA was isolated at 12 h postinfection and used as the
template for RT-PCRs using four different primer pair sets that asymmetrically
flank each of the interconnecting BglI or BstXI junctions that were used in the
assembly of TGEV 1000. RT reactions were performed using Superscript II
reverse transcriptase for 1 h at 50°C as described by the manufacturer (Gibco-
BRL) prior to PCR amplification with the reverse primer that flanked a partic-
ular interconnecting junction. To amplify across the B1-B2 junction, forward
(59-GCATCGTAAGACTCAACAAGG-39) and reverse (59-GTCACAGCAAG
TGAGAACCATG-39) primers were located at nucleotides 9738 to 9759 and
10248 to 10270, respectively, and resulted in a 532-bp amplicon (17). In virus
derived from the infectious construct, BstXI digestion should result in 321- and
211-bp fragments. To amplify across the B2-C junction, forward (59-TTGAGC
GCGAAGCATCAGTGC-39) and reverse (59-TTCCACTGCCGAAAGCTTCA
CC-39) primers were located at nucleotides 11231 to 11151 and 11634 to 11655,
respectively, and resulted in an amplicon of 424 bp (17). In molecularly cloned
virus, BglI digestion should result in products of 300 and 124 bp. To amplify
across the C–DE-1 junction, forward (GAATGTGCACACTAGGACCTG) and
reverse (AGCAGGTGGTATGTATTGTTCG) primers were located at nucleo-
tides 16380 to 16400 and 16936 to 16957, respectively (17). If a BglI site is present
in this 577-bp amplicon, digestion should result in products of 370 and 207 bp. To
amplify across the DE-1–F junction, forward (CGTTGTACAGGTGGTTATG
AC) and reverse (CTCCGCTTGTCTGGTTAGAGTC) primers were located at
nucleotides 23304 to 23324 and 23852 to 23873 in the S gene, respectively (3, 33).
Following BglI digestion of this 569-bp amplicon, 386- and 183-bp fragments
should be visualized in icTGEV virus derived from the infectious construct.
Following 28 cycles of amplification with Taq polymerase (Expand Long Kit;
Roche Biochemical), the PCR products were separated and isolated from aga-
rose gels. PCR amplicons were either subcloned directly into pGemT cloning
vectors for sequencing or digested with BglI or BstXI restriction endonuclease
according to the manufacturer’s directions (NEB). The digested DNAs were
then separated in 1.5% agarose gels in TAE buffer and visualized under UV
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FIG. 1. Strategy for directionally assembling a TGEV infectious construct. (A) The TGEV genome is a linear positive-polarity RNA of about 28,500 nucleotides.
Using RT-PCR and unique oligonucleotide primer mutagenesis, five clones spanning the entire TGEV genome were isolated using standard recombinant DNA
techniques. Unique BglI sites were inserted at the junctions between each clone, a unique T7 start site was inserted at the 59 end of clone A, and a 25-nucleotide T
tail and downstream NotI site were inserted at the 39 end of clone F. The approximate location of each site is shown. (B) Cloning the TGEV B amplicon. Because of
chromosomal instability in E. coli, it was noted that two B clones (TGEV B1 and B3) contained large insertions at nucleotide 9973 in the TGEV genome (17). Other
TGEV B clones had deletions across these sequences. Assuming that these insertions and deletions were “detoxifying” poison TGEV sequences in E. coli, we bisected
the B fragment by inserting a BstXI site at position 9949 and cloning two separate clones designated TGEV B1-1,2 and TGEV B2-1,2. Quasispecies variation in the
sequence of each independent plasmid clones is shown, with conserved changes denoted with asterisks. These conserved changes differed from the published sequence
reported by Eleouet et al. (17) but were identical to the sequence reported by Almazan et al. (3). To reconstruct a wild-type B1 fragment, an SfiI-PflI fragment from
B1-1 was isolated and inserted into the TGEV B1-2 backbone to produce a consensus B1 clone.
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light. All sequence comparisons were performed using the Vector Suite II (In-
formax Inc.) Align X program.
RESULTS
Theoretical framework. Conventional restriction enzymes,
such as PstI and EcoRI, leave sticky ends that assemble with
similarly cut DNA fragments in the presence of DNA ligase
(39) (Table 2). Assuming a random sequence, the rare cutters
(NotI, etc.) recognize an 8-nucleotide palindrome sequence
and cleave DNA on average every 65,000 bp (39). This class of
restriction enzymes leave compatible ends that randomly con-
catamerize or reassemble with other DNA molecules having a
similar compatible end. In contrast, a subclass of restriction
enzymes (BglI, BstXI, and SfiI) also recognize palindrome se-
quences but leave random sticky ends of 1 to 4 nucleotides in
length that are not complementary to most other sticky ends
generated with the same enzyme at other sites in the DNA.
The BglI restriction endonuclease recognizes the palindrome
sequence GCCNNNN2NGGC and is predicted to cleave the
DNA every ;4,096 bp in a random DNA sequence (39). Be-
cause a 3-nucleotide variable overhang is generated follow-
ing cleavage, 64 (43) different variable ends can be generated,
which efficiently assemble only with the appropriate 3-nucleo-
tide complementary overhang generated at an identical BglI
site (Table 2). Consequently, identical BglI sites are repeated
every ;262,144 bp in a random sequence of DNA.
As DNA and RNA sequences are not random, the actual
distribution of these restriction sites will vary considerably and
be heavily influenced by the sequence of the genome, percent
base pair composition, and the presence of duplications, inver-
sions, and repetitive sequences. To address these questions, we
determined the frequency of BglI, SapI, BstXI, SfiI, and EcoRI
sites in the genome of a variety of microbial and viral patho-
gens, including Marburg virus, TGEV, various herpesviruses,
fowlpox virus, and Campylobacter jejuni and Mycoplasma geni-
talium (Table 2). These data clearly demonstrate that the ex-
pected repeat distance of identical BglI sites in a given genome
may be far less than or greater than once every 262,144 bp
(Table 2). For example, the large genomes of C. jejuni and M.
genitalium are devoid of SfiI sites, yet the genome of Epstein-
Barr virus contains 68 SfiI sites because of its high GC content
and the presence of duplications in the sequence. Potential
problems of identical-end duplicity, however, can be circum-
vented if the DNA pieces are cleverly sorted using recursive
techniques, allowing the assembly of approximately 264 frag-
ments of various sizes that contain different BglI ends. Impor-
tantly, these data suggest that the genomes of many microbial
organisms can be engineered and then assembled by in vitro
ligation from a series of smaller subclones. As the TGEV
genome contains a single BglI site (Table 2), we hypothesized
that a sequential series of smaller DNA subclones, each
flanked by unique BglI junctions, could be systematically and
precisely assembled into an intact full-length TGEV cDNA
construct from which in vitro transcription will result in an
infectious RNA (Fig. 1). To test this hypothesis, we assembled
a full-length infectious construct of a coronavirus, thereby
demonstrating the method’s potential application for assem-
bling other large genomes or chromosomes in vitro.
Assembly of a full-length TGEV construct. Initially, we iso-
lated five cDNA subclones spanning the entire TGEV genome
(designated TGEV A, B, C, DE, and F). Each cDNA subclone
was flanked by unique BglI sites and will only anneal with the
appropriate adjacent subclone, resulting in a full-length TGEV
cDNA construct (Fig. 1A). To RT-PCR clone the 6.2-kb





































































































































































































































































































































































































































































































































































































































































































































































































VOL. 74, 2000 STRATEGY FOR ASSEMBLY OF LARGE GENOMES 10603
the forward primer included a T7 start site and the 59-most
TGEV leader RNA sequences, while the reverse primer was
located at nucleotide 6180, just downstream from a naturally
occurring BglI site (GCCTGTT2TGGC) in the TGEV ge-
nome (3, 17) (Table 1). The 5.2-kb B fragment was amplified
using a forward primer upstream of the BglI site at position
6159 and a reverse primer which introduced a unique BglI site
(GCCGCAT2CGGC) at position 11355 (Fig. 1). The 5.2-kb C
fragment was amplified using a forward primer which intro-
duced the same BglI site at nucleotide 11355 and a reverse
primer which introduced another unique BglI site (GCCTTC
T2TGGC) at position 16595. While our original cloning strat-
egy called for separate D and E fragments, it became evident
that a single 6.9-kb fragment was stable in microbial vectors.
Therefore, a single DE-1 fragment was amplified using a for-
ward primer that introduced the same BglI site at position
16595 and a reverse primer which introduced a new BglI site
(GCCGTGC2AGGC) in the S glycoprotein gene at nucleo-
tide 23487. The F fragment was cloned with a forward primer
that introduced the same BglI site at position 23487 and a
reverse primer that contained the 39-most nucleotides of the
TGEV genome, including an additional 25 T’s prior to termi-
nating at a NotI site. A list of the primers used to mutagenize
the TGEV genome and to isolate each of the TGEV subclones
FIG. 2. Sequence and chromosomal location of the TGEV subclones. The consensus amino acid changes that differ from the published sequence are shown in each
of the final clones used to assemble a full-length TGEV construct (17). Each of these changes in the TGEV sequence has also been noted by Almazan et al. (3) at all
indicated positions except those denoted by an asterisk. The relative locations of the different TGEV motifs were taken from Eleouet et al. (17). Abbreviations: PL,
papain-like protease; GFL, growth factor-like domain; Pol, polymerase motif; MIB, metal-binding motif; Hel, helicase motif; VD, variable domain; CD, conserved
domain; 1, intergenic starts.











Actual no. of restriction sitesc (% with nonunique ends)
MV VZV EBV FP MG HH6 CJ TGEV
BglI GCCNNNN2NGGC 3 4,096 (8,640 6 23,266) 262,144 1 (0) 32 (38) 198 (ND) 3 (0) 8 (0) 19 (26) 57 (79) 1 (0)
CGGN1NNNNCCG
BstXI CCANNNNN2NTGG 4 4,096 1,048,576 3 (0) 31 (6) 80 (41) 16 (13) 103 (ND) 33 (12) 135 (ND) 3 (0)
GGTN1NNNNNACC
SfiI GGCCNNNN2NGGCC 3 65,536 4,194,304 0 2 (0) 68 (62) 0 0 2 (0) 0 0
CCGGN1NNNNCCGG
SapI GCTCTTCN2NNN 3 16,384 1,048,576 2 (0) 11 (18) 34 (35) 10 (60) 27 (30) 14 (29) 220 (ND) 4 (0)
CGAGAAGNNNN1
EcoRI G2AATTC 0 4,096 4,096 3 15 15 71 74 52 283 7
CTTAA1G
a Mean distance between BglI sites (in base pairs) in the genomes of these organisms (fragment sizes ranged from 9 to 191,414 bp).
b Frequency of end compatibility with a random sequence.
c MV, Marburg virus (19,104-bp genome; NC001608); VZV, varicella-zoster virus (124,884-bp genome; X04370); EBV, Epstein-Barr virus (172,281-bp genome;
V01555); FP, fowl pox virus (288,539-bp genome; AF198100); MG, M. genitalium (580,074-bp genome; NC000908); HH6, human herpesvirus 6B strain Z29 (162,114-bp
genome; AF157706); CJ, C. jejuni (1,641,481-bp genome; NC002163); TGEV, 28,586-bp genome (3). ND, not done.
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is shown in Table 1. These primer pairs did not alter the ami-
no acid coding sequence of the virus. The sequence of each
unique interconnecting junction is shown in Fig. 1.
The pTGEV A, C, DE, and F clones were stable in plasmid
DNAs in Escherichia coli. The B fragment, however, was un-
stable, and only a few slow-growing isolates were obtained, all
of which contained deletions or insertions in the wild-type
sequence. During two different cloning attempts, a 200- to
300-nucleotide fragment from the E. coli chromosome was
inserted at position 9973, which is in a region of instability in
the TGEV genome noted by other investigators (Fig. 1B) (3,
17). In addition, some clones contained a ;500-bp deletion
across this region. We reasoned that breaks in the TGEV B
sequence at or around nucleotide 9973 might ablate fragment
instability and allow the cloning of these sequences into E. coli.
Since the TGEV B fragment does not contain a BstXI site, we
used primer-mediated mutagenesis (C-A change at position
9944) to bisect the B fragment into TGEV B1 and TGEV B2
amplicons with an adjoining BstXI (CCATTCAC2TTGG) site
located at position 9949 in the TGEV genome (Fig. 1, Table 1).
The 4-nucleotide overhang generated by BstXI would also pro-
vide additional specificity and sensitivity in systematically
assembling the TGEV subclones. After these modifications,
pTGEV B1 and B2 plasmid subclones which were stable and
grew efficiently in E. coli were rapidly identified. The loca-
tion of each of the subclones used in the assembly of the
TGEV full-length construct is shown in relationship to impor-
tant motifs or cis-acting sequences in the viral genome (Fig. 2).
Data from our lab and others suggest that sequences in and
around the TGEV poliovirus 3C-like protease (3-Clpro) motif
are either bactericidal or unstable in microbial vectors (3, 17).
Inserts from three to six independent subclones from each
fragment were sequenced, and a consensus TGEV subclone
was assembled using standard recombinant DNA techniques.
The consensus sequence of our Perdue TGEV full-length con-
struct contained 15 amino acid changes and numerous silent
changes compared with the published sequence (Fig. 2) (17).
These changes were also noted by Almazan et al. (3). T7 ter-
mination sites might also prevent efficient in vitro transcription
of infectious full-length TGEV transcripts from the construct.
Two types of sites are known to cause pausing and/or termi-
nation by bacteriophage T7 RNA polymerase (28, 37). A type
I termination site consists of a stable stem-loop structure that
terminates transcription in adjacent stretches of T residues,
while a type II pause site consists of a specific 7-bp sequence
(ATCTGTT) (28, 37). Transcription termination will occur
when a stretch of T’s is located 6 to 8 nucleotides downstream
of this sequence (28, 37). Type I stops had prevented transcrip-
tion of vesicular stomatitis virus full-length negative-strand
RNAs in vitro with T7 polymerase (58). To preempt potential
problems in the generation of full-length TGEV transcripts,
FIG. 3. Assembly of the TGEV full-length construct. (A) The various TGEV
plasmid DNAs were digested with BglI, BstXI, or NotI, and the appropriate-sized
products were isolated from agarose gels as described in the text. The TGEV A
and B1 fragments, TGEV B2 and C3 fragments, or TGEV DE-1 and F fragments
were ligated at 16°C overnight in separate reactions. Appropriate-sized products
were isolated from agarose gels. (B) A1B1. (C) B21C. (D) DE-11F. Following
purification from agarose gels, the purified products are shown in panel A as well.
FIG. 4. In vitro transcription from full-length TGEV constructs. The A-B1, B2-C, and DE-1–F contigs were ligated in vitro as described in the text. (A and B) DNA
positions after 8 and 30 h of electrophoresis, respectively. Lane 1, purified A-B1 product; lane 2, purified B2-C product; lane 3, purified DE-1–F product; lane 4, 1-kb
ladder; lane 5, in vitro-ligated products; lane 6, high-molecular-weight markers. (C) The in vitro-ligated products were transcribed in vitro, and the products were
digested with DNase for 15 min at room temperature and separated in agarose gels. Lane 1, high-molecular-weight DNA markers; lane 2, 1-kb DNA ladder; lane 3,
in vitro-ligated TGEV products; lane 4, DNase-treated in vitro transcripts. Arrow indicates high-molecular-weight transcripts.
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putative type I T7 RNA polymerase termination sites (long
runs of six T’s) were identified in the TGEV consensus se-
quence that starts at nucleotide 3632 in the pTGEV A sub-
clone and 13615 in the pTGEV C subclone (3, 17). Mutations
were introduced by primer-mediated overlapping PCR mu-
tagenesis without altering the coding sequence. Putative type II
pause sites were also identified at nucleotides 17551, 19957,
and 23103 in the TGEV genome (3), but did not contain the
prerequisite downstream T-rich stretch necessary for efficient
T7 termination.
To assemble a full-length cDNA construct of TGEV, plas-
mids were digested with BglI, BstXI, or NotI, and the appro-
priate sized inserts were isolated from agarose gels (Fig. 3A).
The TGEV A and B1, B2, and C, and DE-1 and F fragments
were ligated overnight in the presence of T7 DNA ligase.
Systematically assembled products were isolated from agarose
gels (Fig. 3B to D), and the TGEV A-B1, B2-C3, and DE-1–F
fragments were religated overnight. The final products were
purified by phenol-chloroform-isoamyl alcohol and chloroform
extraction, precipitated under ethanol, and then separated in
agarose gels (Fig. 4A and B). Clearly, an appropriately sized
full-length TGEV cDNA of about 29 kb in length (TGEV
1000) was generated as well as some assembly intermediates.
Capped T7 transcripts were synthesized, treated with DNase,
and analyzed in 0.5% agarose gels in parallel with the TGEV
1000 assembled product. These data demonstrate that low lev-
els of high-molecular-weight transcripts were evident following
T7 transcription in vitro (Fig. 4C). Using transcripts driven
from various pSin replicons (encoding GFP or T7 polymerase)
as a control, we predict that these TGEV transcripts were like-
ly full length (data not shown). DNase treatment removed the
TGEV full-length cDNA as well as the incomplete assembly
intermediates (Fig. 4C).
Transfection and recovery of infectious virus. Synthesis of
full-length TGEV transcripts was difficult but resulted in high-
molecular-weight RNA product (Fig. 4C). To enhance trans-
fection efficiencies, we tested several different strategies to
maximize infectivity of the putative full-length transcripts in
vitro. Under identical conditions of treatment, about 10 to
20% of ST cells are efficiently transfected with Sindbis repli-
cons encoding GFP (1), compared with about 60 to 80% of the
BHK cells (data not shown). As coronavirus host range spec-
ificity occurs primarily at entry and the genomic RNA is infec-
tious in a variety of permissive and nonpermissive cells (5, 14,
41, 44, 51), we reasoned that BHK cells might be more sensi-
tive primary hosts because of the intrinsically higher transfec-
tion efficiency. In addition, several reports have suggested that
the coronavirus N nucleocapsid protein may function as part of
the transcription complex and may influence the translation
efficiency of viral mRNAs (7, 15, 49). Because these data sug-
gested that N might enhance the infectivity of full-length tran-
scripts, four different transfection strategies were tested in
BHK cells. We transfected BHK cells with TGEV transcripts
alone, TGEV plus TGEV N gene transcripts, or just TGEV N
transcripts. In a parallel experiment, TGEV and TGEV N gene
transcripts were treated with RNase A prior to transfection.
Following electroporation, the BHK cells were seeded with 106
ST cells to serve as appropriate permissive hosts for progeny
virus amplification.
Three days posttransfection, supernatants were passaged
into ST cells, and cytopathic effect was observed within 36 h
postinfection only with supernatants derived from the TGEV-
FIG. 5. Plaque morphology of icTGEV viruses. Cultures of ST cells were infected with wild-type (WT) TGEV, icTGEV-1, and icTGEV-3. Cells were stained with
neutral red at 48 h postinfection, and images were digitized and prepared using PhotoShop 5.5.
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N gene-transfected cultures. Supernatants were harvested at
48 h postinfection and passaged twice more at 48-h intervals in
fresh ST cell cultures. Cytopathic effect typical of TGEV in-
fection was evident at each passage (data not shown). Fluores-
cent antibody staining with mouse anti-TGEV serum demon-
strated that viral antigen was clearly present in each passage
(data not shown). Using RT-PCR with primer pairs located
within the leader RNA sequence and at the 39 end of the
TGEV genome, leader-containing subgenomic mRNA tran-
scripts (mRNAs 6 and 7) encoding the N and hydrophobic
membrane proteins were also evident in passage 1 ST cells
(data not shown). Furthermore, virus derived from the TGEV
1000 transcripts was diluted and inoculated into ST cells,
where plaques developed after 48 h (Fig. 5). No significant
differences in plaque morphology were noted between the mo-
lecularly cloned recombinant viruses and wild type, suggesting
that the cDNA construct did not contain debilitating muta-
tions. Transcripts of TGEV plus N gene treated with RNase A
prior to electroporation did not result in the production of in-
fectious virus.
Plaque-purified stocks prepared from passages 1 through 3
of icTGEV (icTGEV-1, icTGEV-2, and icTGEV-3, respec-
tively) were used in growth curves and compared to the pa-
rental TGEV strain in ST cells. Cultures were infected with
virus at an MOI of 5 for 1 h, and samples were harvested at
selected times over the next 44 h. No significant differences in
the replication of wild-type TGEV- or TGEV 1000-derived
viruses icTGEV-1, icTGEV-2, and icTGEV-3 were noted in
ST cells, and all viruses replicated to titers that approached 108
PFU/ml within 28 h (Fig. 6). These data indicate that viruses
derived from the infectious cDNA construct had phenotypes
indistinguishable from those of wild-type TGEV in swine cells.
TGEV efficiently utilizes the feline and porcine aminopep-
tidase N receptors for docking and entry and can replicate
efficiently in feline CRFK cells (14, 51) (data not shown). To
determine the host range phenotype of these viruses, cultures
of ST and CRFK cells were infected with the molecularly
cloned icTGEV-1 or icTGEV-3 virus at an MOI of 5 and fixed
at 12 h postinfection. Viral antigen expression was measured
by FA (Fig. 7). Efficient virus docking and entry were evi-
denced by significant levels of antigen expression in swine and
feline cells infected with the molecularly cloned viruses. These
data demonstrate that the molecularly cloned viruses had a
host range phenotype similar to that of the wild type.
Identification of marker mutations. Infectious virus derived
from transfected cultures should contain the four unique in-
terconnecting junction sequences used in the construction of
FIG. 6. Growth curves of plaque-purified molecularly cloned viruses. Plaque-
purified wild-type TGEV and recombinant TGEV viruses (icTGEV-1, icT-
GEV-2, and icTGEV-3) derived from the infectious construct were inoculated
into ST cells at an MOI of 5 for 1 h at room temperature. The virus was removed,
and the cultures were incubated in complete medium at 37°C. Samples were
harvested at the indicated times and assayed by plaque assay in ST cells.
FIG. 7. Host range phenotype of molecularly cloned icTGEV. Cultures of ST or CRFK cells (105) were inoculated with molecularly cloned viruses icTGEV-1 and
icTGEV-3 at an MOI of 5 for 1 h at room temperature. The inocula were removed, and the cells were incubated in complete medium at 37°C for 12 h. Medium was
removed, and the cells were fixed in a 50% methanol–acetone mix, washed, and stained by FA as described in the text. (A) Mock-infected ST. (B) icTGEV-1-infected
ST cells. (C) icTGEV-3-infected ST cells. (D) Mock-infected CRFK cells. (E) icTGEV-1-infected CRFK cells. (F) icTGEV-3-infected CRFK cells.
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the infectious TGEV 1000 construct (Fig. 1 and 2). If these
noncoding mutations produce a neutral phenotype on virus
replication, they should also be stable during passage. Conse-
quently, wild-type TGEV, icTGEV-1, and icTGEV-3 were in-
oculated into ST cells, and intracellular RNA was isolated at
12 h postinfection. Using RT-PCR and primer pairs that asym-
metrically flank each of the B1-B2, B2-C, C–DE-1, and DE-
1–F junctions, we amplified products of ;400 to 600 bp (Fig.
8). Results using restriction fragment length polymorphism
analysis demonstrated that none of the marker mutations
were present in the wild-type TGEV genome (Fig. 8A). How-
ever, the icTGEV-1 and icTGEV-3 viruses both contained the
unique marker mutation profiles used to create the unique BglI
and BstXI restriction sites within the TGEV 1000 construct
(Fig. 8B and C). The PCR products were subcloned, and the
reverse complement of the sequence is shown, demonstrating
that the appropriate mutations were present in the viruses
isolated from the infectious construct (Fig. 9). Clearly, TGEV
1000 transcripts were infectious and produced virus which con-
tained the appropriate marker mutations. These data illustrate
that infectious constructs of coronaviruses can be systemati-
cally and precisely assembled from a series of smaller sub-
clones in vitro.
DISCUSSION
The complete ;30-kb nucleotide sequence for a number of
coronaviruses has been available for about 10 years (8, 17, 22,
27), yet until recently, a full-length infectious clone has not
been assembled because of size constraints and regions of
coronavirus genomic instability in bacterial vectors, the re-
quirement for a vector system which allows simple reverse
genetic applications, and the inability to synthesize full-length
transcripts in vitro. Each of these inherent restrictions must be
circumvented to assemble infectious coronavirus constructs
and at the same time allow easy reverse genetic applications. In
a landmark achievement, a full-length TGEV infectious clone
was recently engineered into BAC vectors using standard DNA
techniques (3). Following DNA transfection into ST cells, full-
length transcripts were initially transcribed from a cytomega-
lovirus (CMV) promoter and then amplified by virus replica-
tion in the cytoplasm of the cell. In this paper, we describe a
rapid approach to systematically assembling a full-length in-
fectious TGEV cDNA from a panel of six smaller subclones
using in vitro ligation. These methods will provide a powerful
complementary approach to systematically assemble new large
FIG. 8. Marker mutations are present in virus derived from the infectious
construct. Cultures of ST cells were infected with wild-type (WT) TGEV or
plaque-purified icTGEV isolates derived from the infectious construct. Intra-
cellular RNA was isolated, and RT-PCR was performed using primer pairs
that asymmetrically flank each of the unique BglI-BstXI junctions inserted into
the infectious construct. (A) Wild-type TGEV. (B) icTGEV-1 (passage 1). (C)
icTGEV-3 (passage 3). In panel C, a larger ;1.6-kb wild-type TGEV amplicon
spanning the B1-B2 junction was also treated with BstXI as a control (the
amplicon was derived from primer pairs located between nucleotides 9730 and
9750 and 11342 and 11362 in the TGEV sequence [3]). Arrows indicate cleaved
DNA intermediates.
FIG. 9. Sequence analysis of icTGEV-3. The uncut RT-PCR amplicons
shown in Fig. 8 were isolated from gels and subcloned into Topo II TA cloning
vectors. Inserts were sequenced using universal primers and an automated se-
quencer. (A) icTGEV-3 B2-C junction. (B) icTGEV-3 C-DE junction. (C)
icTGEV-3 DE-F junction. Note: sequences are the reverse complement of the
genomic TGEV sequence. The wild-type virus sequence is also noted in each
panel.
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cDNAs from a variety of microbial pathogens into BAC or
other vectors that stably maintain large DNA inserts (30).
Importantly, RNA or DNA genomes which are too large, cir-
cular, or unstable in these cloning vectors can still be assem-
bled using this in vitro ligation technique. As coronaviruses
contain the largest RNA genome, these approaches should
permit reverse genetic studies for all RNA viruses.
Evidence from several experiments demonstrated that tran-
scripts of the TGEV 1000 genomic construct were infectious.
Transcripts treated with RNase were not infectious, indicating
that infection was likely initiated from the RNA transcripts
synthesized in vitro. Medium from transfected cultures could
be used to propagate infection, with corresponding cytopathol-
ogy and viral antigen expression in fresh cultures of cells.
Progeny virions formed plaques in monolayers of permissive
cells, and plaque-purified molecularly cloned virus grew effi-
ciently to levels equivalent to those of wild-type virus in per-
missive host cells. The host range phenotypes of molecularly
cloned viruses and wild-type virus were similar in vitro,
although additional experiments are needed to determine if
these viruses utilize the feline aminopeptidase receptor for
docking and entry into feline cells (51). Most importantly,
plaque-purified virus contained the expected BglI and BstXI
marker mutations, providing definitive evidence that tran-
scripts driven from the TGEV 1000 construct were infectious
in vitro. The presence of these neutral mutations did not re-
strict the ability of icTGEV to replicate efficiently in ST cells.
It is remarkable that two entirely different approaches can
be exploited to engineer infectious constructs of large RNA
and DNA viruses. Our assembly strategy for coronavirus in-
fectious constructs is simple and straightforward and does not
depend on the availability of an existing viral defective inter-
fering cDNA clone as a foundation for building the infectious
construct (3). In contrast to infectious clones of other positive-
strand RNA viruses (1, 2, 3, 13, 32, 35, 54), the TGEV 1000
construct must be assembled de novo and does not exist intact
in bacterial vectors, circumventing problems in sequence insta-
bility. This did not restrict its applicability for reverse genetic
applications, but rather allowed genetic manipulation of inde-
pendent subclones, which will minimize the introduction of
spurious mutations elsewhere in the genome during recombi-
nant DNA manipulation. Another advantage of our approach
is that different combinations of restriction sites can be used
that generate highly variable 59 or 39 overhangs of 1 to 4 nu-
cleotides in length, further increasing the specificity and sen-
sitivity of the assembly cascade (Table 2). Because of insert
toxicity in E. coli, infectious clones of yellow fever virus and
Japanese encephalitis virus were assembled by in vitro ligation
from two subclones but used conventional restriction enzymes
like BamHI, ApaI, and AatI (34, 48). Our strategy, however,
prevents spurious self-assembly of subclones and will provide a
strong complementary approach to engineering large RNA or
DNA genomes into BAC vectors or other vectors that stably
maintain large DNA inserts (3).
It is interesting that in both TGEV infectious constructs
assembled to date, sequences in or around the TGEV 3-Clpro
motif were unstable in E. coli. Our studies, coupled with the
findings by Almazan et al. (3), suggest that the unstable se-
quences can be disabled by bisecting the sequence between
nucleotides 9758 and 9949 in the TGEV genome. This infor-
mation may permit the isolation of larger TGEV A-B1, B2-C,
and DE-F subclones and allow the assembly of infectious
cDNAs following a single DNA isolation-ligation step. It is not
clear whether similar unstable sequences are located at this
position in other group 1 and group 2 coronaviruses.
Synthesizing ;29-kb transcripts in vitro is problematic and
the greatest impediment to generating infectious RNA from
the assembled TGEV 1000 construct. Using a DNA launch
platform and transcription of TGEV RNAs from a CMV pro-
moter, transfection resulted in ;36 infectious units/10 mg of
DNA (3). Using an RNA launch platform, similar results were
obtained in our laboratory. Compared with Sindbis virus rep-
licons encoding GFP, we synthesized ;100-fold less full-length
TGEV transcripts in vitro, probably due to the extreme size of
the viral genome (data not shown). Using transcripts driven
from the ;28.5-kb TGEV full-length construct alone, viral
structural gene expression was not noted in 105 cells. In BHK
cultures cotransfected with TGEV and N gene transcripts,
;100 to 500 cells per 105 cells expressed viral structural pro-
teins under identical conditions (data not shown). At 16 h
posttransfection, little if any structural protein expression was
noted in BHK cells electroporated with N gene transcripts
alone or transcripts treated with RNase A. This compares with
transfection efficiencies of greater than 60% using the 11- to
12-kb Sindbis virus noncytopathic replicons encoding GFP.
Although less dramatic, similar problems were reported with
the ;13-kb infectious arterivirus cDNA clone (54). These
problems may be circumvented somewhat by constructing
BHK cell lines that simultaneously express the swine amino-
peptidase N receptor and T7 RNA polymerase, allowing DNA
transfection and transcription in vivo, and direct selection of
progeny virus amplification in susceptible BHK cell lines (1, 14,
51). Alternatively, CMV promoters can be inserted at the 59
end of the TGEV A clone, allowing DNA launch of infectious
RNA (3).
In our studies, we could not generate infectious full-length
transcripts until the putative T7 polymerase stop signals were
removed from the TGEV genome, cytidine was included in
agarose gels to reduce UV damage to DNA fragments, and
BHK cells were used as recipient hosts (21). At this time, we
have no direct evidence that the T stretches in the TGEV A
and C fragments might act as T7 termination sites, as the RNA
structure in these regions has not been characterized biochem-
ically. Inclusion of capped N gene transcripts during the trans-
fection process also enhanced the infectivity of the TGEV
full-length construct in three separate trials. It is not com-
pletely clear whether these results were simply serendipitous or
whether N transcripts were simply protecting the full-length
transcripts from degradation by competitively interfering with
RNase activity in cells or culture medium. The N protein may
also protect the genome-length RNA in a ribonucleoprotein
structure in the cell, enhance infectivity directly by stabilizing
or functioning as part of an intact replication complex (7, 15,
26), or enhance the expression of viral mRNAs (49). Interest-
ingly, TGEV engineered into BAC vectors did not require the
presence of nucleocapsid protein to enhance transcript infec-
tivity, suggesting an ancillary role for N transcripts in our
system (3).
Prior to these and earlier studies (3), targeted RNA recom-
bination using defective interfering donor RNAs was the best
method for introducing precise alterations into the structural
genes of the group II coronavirus mouse hepatitis virus, but
this approach has been essentially limited to the 39-most 9 kb
of the mouse hepatitis virus genome (24, 25, 53). The avail-
ability of TGEV infectious constructs will obviously benefit
studies of all aspects of TGEV biology and pathogenesis, in-
cluding analysis of the coronavirus replicase and the somewhat
controversial transcription processes which govern expression
of the subgenome-length mRNAs (17, 40, 42, 43). The future
development of TGEV vaccines and expression vectors is a
particularly intriguing application, as the polycistronic genome
organization and synthesis of subgenome-length mRNAs may
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allow the simultaneous expression of multiple foreign genes
(18). It will also be relatively easy to target TGEV to other
species by simple replacements of the S glycoprotein gene (14,
25, 51). In contrast to arterivirus expression vectors, the coro-
navirus intergenic sequences rarely overlap upstream ORFs,
simplifying the design and expression of foreign genes from
downstream intergenic promoters (11, 17, 52). Several TGEV
downstream ORFs also appear to encode luxury functions that
can be deleted from the viral genome without affecting infec-
tivity in vitro (18, 29, 56, 57). Finally, the helical TGEV nu-
cleocapsid structure may minimize packaging constraints and
allow the expression of multiple large genes from a single
construct (18, 26, 36).
The theoretical limits of our technique may approach sev-
eral million base pairs of DNA and provide a rapid approach
for inserting large cDNAs into BAC vectors (20, 30, 45). The
systematic assembly method should be appropriate for con-
structing full-length infectious constructs of other large RNA
viruses, including coronaviruses (27 to 32 kb), toroviruses (24
to 27 kb), and filoviruses like the Ebola and Marburg viruses
(19 kb) (10, 26, 31). Viral genomes which are unstable in pro-
karyotic vectors might also be successfully cloned using these
methods (9, 34, 48). Moreover, full-length infectious double-
stranded DNA genomes of adenoviruses and herpesviruses
promise to be a powerful tool in vaccination, gene transfer, and
gene therapy (30, 45, 50, 55). Historically, full-length infectious
constructs of these DNA viruses have been generated by liga-
tion of DNA fragments, by homologous recombination (the
more widely used method), or as full-length clones in BAC
vectors (30, 38, 45, 50, 55). Direct ligation of DNA fragments
has been restricted by the low efficiency of large-fragment
ligations and the scarcity of unique restriction sites that make
the approach technically challenging. Systematic and precise
assembly using rare cutters (SfiI and SapI) that leave variable
ends and can be purposely engineered into a sequence should
simplify assembly of large double-stranded DNA viruses (Ta-
ble 2). This will alleviate the difficulties associated with typical
restriction enzymes or recombination approaches, which often
result in second-site alterations (38, 45, 50, 55). This method
may also circumvent other restrictions inherent in recombina-
tion-based methods which are limited to specific regions in the
viral genome and which often result in recombinant viruses
which are not wild type while allowing the introduction or
removal of only a few genes in the virus vectors.
Our systematic assembly approach is not limited to manip-
ulating the chromosomes of large RNA and DNA viruses.
Over the past decade, the genome sequence of a large number
of prokaryotic and eukaryotic chromosomes has provided sig-
nificant insight into gene organization, structure, and function
and likely identified the minimal set of genes required for
prokaryotic life (12, 23; TIGR home page http://www.tigr.org).
Reconstruction of a minimal genome from the bottom up is
technically challenging and requires systematically assembling
large DNA fragments and then inserting the reconstructed
genome into an environment that allows metabolic activity and
replication (12). Using a recursive approach, the systematic
assembly of large chromosomes or minichromosomes from the
bottom up is theoretically feasible (Table 2). Technical chal-
lenges will likely include the isolation of large DNA fragments
and accompanying assembly intermediates from gels and the
introduction of large DNA genomes into environments that
permit replication. Our approach, however, may provide a
means to address the function of large blocks of DNA, like
pathogenesis islands, or to directly engineer chromosomes that
contain large gene cassettes of interest (12). Additional studies
will be needed to test the application of these methods in other
viral, prokaryotic, and eukaryotic genomes.
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